Inflammatory bowel disease drug market will reach $9.6bn in 2017

Friday 30 August 2013, Amsterdam

A new report predicts world inflammatory bowel disease (IBD) drug revenues will reach $9.6 billion in 2017. That forecast and others appear in Inflammatory Bowel Diseases: World Drug Market 2013-2023, published in July 2013.

We predict the IBD treatment market will grow in revenues because of the increased use of biological therapies (biologics), such as monoclonal antibodies (mAbs). Although biologics account for a small part of prescriptions, they dominate the market for revenue generation. The strength of this market is also reflected in the 30 new treatments undergoing clinical development to treat IBD.

Hamza Baig, a pharmaceutical industry analyst, said: “The global inflammatory bowel disease market will show robust growth over the next five years. In particular, my expectation is that biologics will drive growth. However, aminosalicylates, the traditional treatment for IBD, will remain an important option for patients, particularly for those residing in emerging markets. This is because a large number of people in these countries do not necessarily have the means to pay for the most expensive biologic therapies. The cost advantage of aminosalicylates will be more pronounced in these countries.

“Our report also finds that developed world markets make up the majority of the global IBD market, but that emerging markets will also show strong growth over the next few years. While inflammatory bowel disease is considered a disease of the developed world, as poorer nations industrialise and urbanise we expect the incidence of these conditions to increase. Among developing nations, Russia and India will show the greatest and second greatest growth rates respectively. I also note the global IBD market is dominated by four main players, who I expect will consolidate their positions over the next 10 years.”

This report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. It forecasts five world-level submarkets:

• Aminosalicylates
• Antibiotics
• Corticosteroids
• Biologic therapies (biological drugs)
• Immunomodulators.

That report also predicts the revenues of the 14 leading inflammatory bowel disease treatments to 2023, including Remicade, Humira and Asacol.

The study analyses the R&D pipeline for IBD treatments too, and shows research interviews. It also shows overall IBD revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC).